Shares of NovoCure (NVCR) were up 7.5% to $20 ahead of the market open on Friday, Nov. 17, after the Saint Helier, Jersey-based oncology firm released results from a retrospective post-hoc analysis of its Phase 3 EF-14 study data that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.
"The analysis showed that an Optune compliance threshold as low as 50 percent correlated with significantly improved outcomes in patients treated with Optune together with temozolomide compared to patients treated with temozolomide alone," Novocure said.
The results were discussed at the Society for Neuro-Oncology's 22nd Annual Scientific Meeting and Education Day, which kicked off Nov. 16 in San Francisco and will run through Nov. 19.
The Phase 3 study compared Optune in tandem with temozolomide to temozolomide alone in 695 patients with newly diagnosed glioblastoma.
Among the other stock movers were Revance Therapeutics Inc. (RVNC) , up 5.1% to $26.80, and Intellia Therapeutics Inc. (NTLA) , down 4.9% to $18.76. Newark, Calif.-based Revance develops botulinum toxin products for use in the treatment of aesthetic and therapeutic conditions. Cambridge, Mass.-based Intellia is a genome editing firm.